

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1

RRID:AB_2142367

Type: Antibody

Proper Citation

Agilent Cat# M7240, RRID:AB_2142367

Antibody Information

URL: http://antibodyregistry.org/AB_2142367

Proper Citation: Agilent Cat# M7240, RRID:AB_2142367

Target Antigen: Ki-67

Host Organism: mouse

Clonality: monoclonal

Comments: Info: Used By NYUIHC-1131.

Info: Original Manufacturer: Dako. Now part of Agilent.

Info: Used by Czech Centre for Phenogenomics

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1

Description: This monoclonal targets Ki-67

Target Organism: human

Clone ID: MIB1

Antibody ID: AB_2142367

Vendor: Agilent

Catalog Number: M7240

Record Creation Time: 20231110T050233+0000

Record Last Update: 20260830T031211+0000

Ratings and Alerts

- Used by Czech Centre for Phenogenomics - Czech Centre for Phenogenomics
<https://www.phenogenomics.cz/>

No alerts have been found for Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 121 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Miyan J, et al. (2026) The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction. bioRxiv : the preprint server for biology.

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. Journal for immunotherapy of cancer, 14(6).

Miller JS, et al. (2026) Neurotensin drives theca cell migration during ovulation in primates†. Biology of reproduction, 114(1), 230.

Tsuruta A, et al. (2026) The circadian clock component BMAL1 enhances macrophage inflammation by nuclear translocation of peroxisomal α -oxidation enzyme MFP2. Cell reports, 45(6), 117480.

Makhmut A, et al. (2026) Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets. Molecular systems biology, 22(1), 7.

Saurat N, et al. (2026) Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration. Cell stem cell, 33(2), 355.

Miyan J, et al. (2026) The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment. Cancers, 18(6).

Hernández-Verdin I, et al. (2026) GABA promotes resistance to immunotherapy in patients with TLS-positive tumors. Cancer cell.

Sato K, et al. (2026) Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma. *Cancer research communications*, 6(2), 260.

Asmanidou S, et al. (2026) BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. *Cell death & disease*, 17(1), 187.

Berner MJ, et al. (2026) 3D EM uncovers mitochondrial network remodeling in residual triple negative breast cancer after conventional chemotherapy treatments. *iScience*, 29(6), 115865.

Rosado-Sanz M, et al. (2026) Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. *Oncoimmunology*, 15(1), 2687381.

Morris VK, et al. (2025) Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(9), 1657.

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. *Cancer research communications*, 5(3), 444.

Krech M, et al. (2025) Outcome-associated factors in a molecularly defined cohort of central neurocytoma. *Acta neuropathologica*, 149(1), 61.

Brož P, et al. (2025) Molecular Landscape of Pediatric Low-Grade Gliomas: Insights From RNA-NGS and Bioinformatic Analysis. *Genes, chromosomes & cancer*, 64(10), e70085.

Rose EC, et al. (2025) Single-cell transcriptomics predict novel potential regulators of acute epithelial restitution in the ischemia-injured intestine. *American journal of physiology. Gastrointestinal and liver physiology*, 328(3), G182.

Osonoi S, et al. (2025) CCNA2 and CCND2 are differentially involved in β -cell proliferation in perinatal Japanese autopsied subjects. *The Journal of clinical endocrinology and metabolism*.

Koshizuka K, et al. (2025) Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. *Cancer research*, 85(16), 3032.

Le Rochais M, et al. (2025) A Tertiary lymphoid structures-based pathological score predicts survival and recurrence in colorectal Cancer patients. *Immunobiology*, 230(3), 152911.